Abstract
Objective
Investigate the prognostic value of miR-26a/b-5p in endometrial carcinoma (EC), and to analyze the relationship between miR-26a/b-5p and target gene EZH2.
Methods
The expression levels of miR-26a-5p and miR-26b-5p were detected by RT-PCR in 60 cases of EC patients with cancer and normal endometrial tissue adjacent to cancer; Collect medical records of EC patients. To compare the expression difference of miR-26a-5p and miR-26b-5p in cancer tissues and normal endometrial tissues adjacent to cancer, and to compare the expression difference of miR-26a-5p and miR-26b-5p in EC patients with different clinical and pathological characteristics, and to analyze the impact of miR-26a-5p and miR-26b-5p expression levels on survival and prognosis of EC patients. In addition, the target genes of miR-26a-5p and miR-26b-5p were analyzed by bioinformatics analysis to explore their possible mechanisms in the occurrence and development of EC.
Results
The expression levels of miR-26a-5p and miR-26b-5p in cancer tissues were lower than those in adjacent normal endometrial tissues (P < 0.001); In EC patients, the low expression of miR-26a-5p was significantly correlated with lymph node metastasis, poor differentiation of tumor tissue, and positive ascitic heterotypic cells. The low expression of miR-26b-5p was significantly correlated with advanced patients and lymph node metastasis (P < 0.05). The overall survival rate and tumor free survival rate of the miR-26a-5p overexpression group and the miR-26b-5p overexpression group were higher than those of the corresponding low expression group (P < 0.05); The lower expression levels of miR-26a-5p and miR-26b-5p, the late FIGO stage and the age ≥ 55 years old are independent risk factors for the overall survival rate of EC cancer patients, while the lower expression level of miR-26a-5p and lymph node metastasis are independent risk factors for the tumor free survival rate of EC patients (P < 0.05). EZH2 is the key target gene of miR-26a-5p and miR-26b-5p in EC. EZH2 is highly expressed in EC patient samples (P < 0.05), and can affect the survival rate of EC patients.
Conclusion
miR-26a-5p and miR-26b-5p are related to the occurrence and progress of EC, and can affect the survival and prognosis of EC patients. They may be used as biological markers to monitor the progress and prognosis of EC, and have the potential to be new targets for treatment of EC, and miR-26a-5p and miR-26b-5p may regulate the occurrence and development of EC by targeting EZH2.